Abstract: We develop a transport formula for predicting overall cumulative vaccine efficacy through time t (VEðtÞ) to prevent clinically significant infection with a genetically diverse pathogen (e. g., HIV infection) in a new setting for which a Phase III preventive vaccine efficacy trial that would directly estimate VEðtÞ has not yet been conducted. The formula integrates data from (1) a previous Phase III trial, (2) a Phase I/II immune response biomarker endpoint trial in the new setting where a follow-up Phase III trial is planned, (3) epidemiological data on background HIV infection incidence in the new setting; and (4) genomic epidemiological data on HIV sequence distributions in the previous and new settings. For (1), the randomized vaccine versus placebo Phase III trial yields estimates of vaccine efficacy to prevent particular genotypes of HIV in participant subgroups defined by baseline covariates X and immune responses to vaccination Sð1Þ measured at a fixed time point τ (potential outcomes if assigned vaccine); often one or more immune responses to vaccination are available that modify genotype-specific vaccine efficacy. The formula focuses on subgroups defined by X and Sð1Þ and being at-risk for HIV infection at τ under both the vaccine and placebo treatment assignments. For (2), the Phase I/II trial tests the same vaccine in a new setting, or a refined new vaccine in the same or new setting, and measures the same baseline covariates and immune responses as the original Phase III trial. For (3), epidemiological data in the new setting are used to project overall background HIV infection rates in the baseline covariate subgroups in the planned Phase III trial, hence re-calibrating for HIV incidence differences in the two settings; whereas for (4), data bases of HIV sequences measured from HIV infected individuals are used to re-calibrate for differences in the distributions of the circulating HIV genotypes in the two settings. The transport formula incorporates a user-specified bridging assumption function that measures differences in HIV genotype-specific conditional biological-susceptibility vaccine efficacies in the two settings, facilitating a sensitivity analysis. We illustrate the transport formula with application to HIV Vaccine Trials Network (HVTN) research. One application of the transport formula is to use predicted VEðtÞ as a rational criterion for ranking a set of candidate vaccines being studied in Phase I/II trials for their priority for down-selection into the follow-up Phase III trial.
Introduction
Ideally, decisions on licensure and deployment of a vaccine for various settings would be based on direct data on efficacy to prevent a clinical endpoint from Phase III trials in each and every setting. However, there are a vast number of different settings, defined by (1) features of the vaccine regimen such as schedule, dose, adjuvant, delivery vector, combination of components, and vaccine strains; (2) features of study participants such as demographics, genetics, and exposure to the pathogen under study; and (3) features of the pathogen such as genotype, serotype, or other phenotypes. Because resource and ethical constraints prohibit this fully direct approach, regulatory agencies allow decisions to be based on immune response data in a new setting (without direct efficacy data) provided that the selected immune response biomarkers are credibly valid immune correlates of protection (FDA Guidance Document 2007), i. e., are approximately valid surrogate endpoints that can be used to reliably predict the level of vaccine efficacy against the clinical endpoint (Plotkin and Gilbert 2012) . Despite the ubiquity of this application and its critical importance, there do not appear to be published formal statistical formulas that aide such predictions (albeit formulas from other work could certainly be extended to this application). We provide such a bridging transport formula, which lays out the specific component terms that need to be correctly specified or estimated to obtain an accurate prediction, and exposit the several assumptions that are needed, highlighting the difficult challenges posed to succeeding in this objective without collecting the direct efficacy data. We also show how to quantify uncertainty in the prediction, and provide a framework of sensitivity analysis to violation of key assumptions. We develop the formula supposing two experiments, the original Phase III efficacy trial (or series of similar trials) that is used to estimate how type-specific vaccine efficacy varies across participant subgroups defined by baseline covariates and immune responses to vaccination and a subsequent Phase I/II trial in the new setting that measures the same baseline covariates and immune responses. The formula also inputs epidemiological data on background disease incidence in the new setting and genomic epidemiological data on the distributions of pathogen types in the two settings.
Literature for methods tackling a similar objective include Cole and Stuart (2010) and Pearl and Bareinboim's (2011) transport formula, the latter of which uses causal selection diagrams to formally encode knowledge of how the original and new settings differ. We use an alternative approach that encodes the bridging assumptions using the principal stratification framework (Frangakis and Rubin 2002) , which entails expressing how pathogen type-specific vaccine efficacy (VE) in subgroups defined by baseline covariates and immune responses to vaccination, differs between the original and new settings. Moreover, our formula addresses three major issues not addressed in most previous work: (1) time-varying VE; (2) mark-varying VE (the "mark" is a genotypic or phenotypic feature of the infecting pathogen that is only measured in clinical endpoint cases); and (3) the fact that some clinical endpoints occur before the immune responses are measured. In our motivating application of preventive HIV vaccines, all three new issues are important, as VE typically varies over time (e. g., Durham et al. 1998; Robb et al. 2012 ) and varies against different HIV-1 genotypes (e. g., Rolland et al. 2012) , and a sizable fraction of HIV infection events (e. g., about 30 % in Hammer et al. 2013 ) occur before the primary time point for measuring immune responses. Therefore, the proposed transport formula accounts for all five issues of baseline covariate re-calibration, post-randomization intermediate endpoint re-calibration, time-varying vaccine efficacy, mark-varying vaccine efficacy, and early clinical events.
Section 2 describes the randomized trial designs, notation, and parameters of interest. Section 3 provides the transport formula, and Section 4 describes procedures for estimating the terms in the formula and for obtaining uncertainty assessment. Section 5 applies the formula to the HIV example with expanded details relegated to the Supplementary Materials. Section 6 concludes with discussion. Supplementary Materials A discusses how our transport formula can be altered to swap principal stratification treatment effects for controlled effects (Robins and Greenland 1992; Pearl 2001) . It is also of interest to compare our transport formula to those of Pearl and Bareinboim (2011) and their subsequent work; we describe a few connections in Section 3.3.
2 Trial design, notation, vaccine efficacy parameters 2.1 Set-up of the randomized phase III trial for assessing vaccine efficacy
We consider a double-blind clinical trial that randomizes n participants to vaccine or placebo, with Z the indicator of assignment to vaccine. Participants are followed for occurrence of the primary clinical study endpoint, clinically significant pathogen infection (Clements-Mann 1998) , with maximum follow-up τ 1 , and T is the time from randomization until the clinical endpoint. Let S be immune response biomarkers (that are potentially modifiers of vaccine efficacy) measured at fixed time τ < τ 1 post-randomization in vaccine recipients. Because S is expensive to measure, a case-cohort or case-control sampling design is used; let R be the indicator that S is measured. Let X be baseline covariates. Let C be the time from randomization until right-censoring, with Y ≡ minðT, CÞ and Δ ≡ IðY = TÞ. Let V be a "mark" variable measuring features of the infecting pathogen for disease endpoint cases; T and V are only observed if Δ = 1 (Juraska and Gilbert 2013) . In the sixties, D.R. Cox introduced the terminology "mark" to refer to any information collected from failure cases, which is not observable or meaningful until failure occurs (e. g., the sequence of an HIV infecting a person is only observable and relevant once HIV infection occurs). With key paper Prentice et al. (1978) , many statistical methods in the competing risks failure time literature have focused on a discrete mark variable, where the different levels of the mark are the competing risks. A mark is conceptually distinct from a covariate -covariate levels define subgroups who are followed for occurrence of the outcome whereas mark levels define types of the outcome; thus vaccine efficacy parameters of interest condition on covariates but not on marks.
Let WðzÞ ≡ ðRðzÞ, RðzÞSðzÞ, TðzÞ, CðzÞ, ΔðzÞ, VðzÞÞ be the potential outcomes if assigned treatment z, for z = 0, 1, where SðzÞ is defined if and only if TðzÞ > τ. The observed data are O ≡ ðZ, X, R, ZRS, Y, Δ, ΔVÞ. We make the typical assumptions for randomized clinical trials of SUTVA (no-interference between units and only one version of treatment) (Rubin 1978) , ignorable treatment assignment (Z?Wð1Þ, Wð0Þ), random censoring (CðzÞ ? RðzÞ, RðzÞSðzÞ, TðzÞ, VðzÞ) for z = 0, 1, whether S is observed depends only on the observed data O (missing at random), and W 1 , Á Á Á , W n and O 1 , Á Á Á , O n are independent copies of W and O, respectively.
Vaccine efficacy curve parameters for enabling bridging
In general, principal stratification analysis assesses treatment effects in "principal strata subgroups" defined by joint potential outcomes under each treatment assignment (Frangakis and Rubin 2002) . For our problem, we first define principal strata by early failure status IðTðzÞ > τÞ, and secondly intersect Sð1Þ with these principal strata to form a finer stratification that delineates the subgroups for inference. Four principal strata subgroups are defined by the cross-classification of IðTð1Þ > τÞ and IðTð0Þ > τÞ: Early-always-infected (EAI) fi :T i ð1Þ ≤ τ, T i ð0Þ ≤ τg, Early-always-survivors (EAS) fi :T i ð1Þ > τ, T i ð0Þ > τg. Gilbert and Hudgens (2008) and sequel articles including Gabriel and Gilbert (2014) developed methods for estimating the "VE surface," which contrasts risks of the clinical endpoint over time under the two treatment assignments in principal strata defined by the immune response (Sð1Þ, Sð0Þ) in the EAS stratum, the only one of the four in which both Sð1Þ and Sð0Þ are defined: risk z ðtjs 1 , s 0 Þ ≡ PðTðzÞ ≤ tjTð1Þ > τ, Tð0Þ > τ, Sð1Þ = s 1 , Sð0Þ = s 0 Þ,
for z = 0, 1. The closely related marginal VE curve contrasts the treatment-specific clinical risks averaged over the distribution of Sð0Þ, mrisk z ðtjs 1 Þ ≡ PðTðzÞ ≤ tjTð1Þ > τ, Tð0Þ > τ, Sð1Þ = s 1 Þ, where the principal strata of interest are defined by fTð1Þ > τ, Tð0Þ > τ, Sð1Þ = s 1 g.
A transport formula could be developed based on risk z ðÁjs 1 , s 0 Þ or on mrisk z ðÁjs 1 Þ. We restrict attention to the latter marginal risks, with the corresponding conditional cumulative vaccine efficacy defined as
We focus on the marginal risks because they are easier to estimate than the risks, given the lower dimensionality of the principal strata, and because there are many applications amenable to working with the marginal risks. In particular, one major application area has Sð0Þ constant (the "Constant Biomarker" scenario), including for our HIV vaccine example where Sð0Þ is zero in all placebo recipients (Gilbert and Hudgens 2008) . For this application area risk z ðÁjs 1 , s 0 Þ = mrisk z ðÁjs 1 Þ, such that the analysis is identical using risks or marginal risks. In scenarios where Sð0Þ is not constant, the other major application area where the marginal risks approach works is if one can assume that Sð0Þ does not modify vaccine efficacy after accounting for Sð1Þ and X. While this is typically a strong assumption warranting caution, there may be applications where the assumption is plausible, for example if X includes a measurement of S at baseline, such that Sð0Þ is a repeated measure of the same variable measured at baseline (Gabriel and Gilbert 2014) .
We similarly define the mark-specific VE curve, VEðt, vjs 1 Þ ≡ 1 − mrisk 1 ðt, vjs 1 Þmrisk 0 ðt, vjs 1 Þ, where mrisk z ðt, vjs 1 Þ ≡ PðTðzÞ ≤ t, VðzÞ = vjTð1Þ > τ, Tð0Þ > τ, Sð1Þ = s 1 Þ for z = 0, 1. The parameters may also condition on X: VEðt, vjs 1 , xÞ = 1 − mrisk 1 ðt, vjs 1 , xÞ=mrisk 0 ðt, vjs 1 , xÞ, VEðt, vjxÞ ≡ 1 − risk 1 ðt, vjxÞ=risk 0 ðt, vjxÞ, and VEðtjxÞ = 1 − risk 1 ðtjxÞ=risk 0 ðtjxÞ, with risk z ðt, vjxÞ ≡ PðTðzÞ ≤ t, VðzÞ = vjTð1Þ > τ, Tð0Þ > τ, X = xÞ and risk z ðtjxÞ ≡ PðTðzÞ ≤ tjTð1Þ > τ, Tð0Þ > τ, X = xÞ. Study of these VE curves is a study of effect modification -how does VE vary with ðX, Sð1ÞÞ across EAS subgroups defined by (X, Sð1Þ)? Table 1 defines the terms needed for the transport formula. We develop the results assuming "No-early-VE", PðIðTð1Þ > τÞ = IðTð0Þ > τÞÞ = 1, which implies that the EH and EP strata are empty and can be ignored, greatly simplifying identifiability. No-early-VE has been assumed in most articles on the evaluation of principal surrogate endpoints, and is discussed further in Section 3.4. We also develop the results relaxing No-early-VE to "No-early-harm", PðTð1Þ ≤ τ, Tð0Þ > τÞ = 0, under which the EP stratum may not be empty and must be dealt with. This second approach allows beneficial VE before the immune responses are measured, which can readily occur (e. g., Capeding et al. 2014; Villar et al. 2015) . Because it is more complicated, we relegate it to Supplementary Materials B. The No-early-harm assumption is a monotonicity assumption commonly used in causal inference that simplifies identifiability, and No-early-VE is a stronger version that is equivalent to monotonicity in both directions.
Is use of a surrogate endpoint S critical for bridging?
Traditionally, bridging is based on a surrogate (i. e., replacement) endpoint, which may be defined conceptually as an intermediate response endpoint measured in both treatment groups that can be used for reliable inferences about clinical treatment efficacy without needing to measure the clinical endpoint (FDA Guidance Document 2007). Here we avoid the term surrogate, because the needed attribute of S for the transport formula is that it modifies vaccine efficacy, and being an effect modifier is a distinct property from being a valid surrogate endpoint . For example, our transport formula makes no assumptions about whether S satisfies the Prentice (1989) criteria for a valid surrogate endpoint; rather it requires inclusion of all effect modifiers S regardless of the extent to which they adhere to the Prentice criteria.
3 Immuno-bridging transport formula 3.1 Set-up Suppose a previous Phase III vaccine efficacy trial showed significant overall benefit VEðtÞ > 0 for a fixed time t 2 ðτ, τ 1 of interest, as for our motivating example the RV144 trial. Our goal is to estimate VEðtÞ in a new setting of interest based on (1) the estimated VEðt, vjs 1 , xÞ curve from the previous Phase III trial(s), (2) assumptions about how this curve transports to the new setting, and (3) data on the distributions of X, Sð1Þ, V, and (4) information on background risk mrisk 0 ðt, vjs 1 , xÞ in the new setting. A Phase I/II randomized trial is conducted in the new setting, which randomizes m participants to the new vaccine or new placebo (Z = 1 * or Z = 0 * ), and uses identical procedures for measuring the same covariates X and immune responses Sð1Þ.
Participants are followed until time τ when samples are collected for measuring Sð1Þ. estimating VE * ðtÞ for a fixed time t 2 ðτ, τ 1 based on the full data set from the previous efficacy trial and on the data set ðZ which measures the ratio of vaccine efficacies for the new and original settings for each value of ðt, v, s 1 , xÞ, thereby expressing a bridging assumption of how the mark-specific VE curve differs in the two settings. This ratio has approximate interpretation as the ratio of multiplicative vaccine-reductions in average markspecific per-exposure probabilities of acquisition of HIV , which aids thoughtful specification of ϕðÁÞ. Specification of bridging assumptions through the function ϕðÁÞ is a key difference of the current approach compared to Pearl and Bareinboim's (2011) approach.
Transport formula
For any fixed t 2 ðτ, τ 1 , the "immuno-bridging transport formula" is [3], and assuming a specified form for ϕðt, vjs 1 , xÞ. We next list a set of assumptions sufficient for consistently estimating VE d* ðtÞ and VE * ðtÞ using the formula, followed by some proposed approaches to estimating terms. The list of the assumptions will make evident that it is highly challenging to assure valid implementation of the transport formula. Indeed, an objective of this work is to explain in specific and component terms the challenges posed to reliably inferring VE * ðtÞ in a new setting without directly estimating VE * ðtÞ using the clinical endpoint data.
Assumptions for the transport formula
The set of assumptions needed for the transport formula to provide consistent estimates of VE d* ðtÞ and VE * ðtÞ for a fixed t 2 ðτ, τ 1 are listed below. The common support assumption 3(A) is needed for the transport formula to provide empirical estimates of VE * ðtÞ; without it, the formula can only provide predictions of VE * ðtÞ for what-if modeling scenarios. The critical assumptions 3(B) and 3(C) require subject-matter knowledge for achieving plausibility. Because the three major factors (1) VEðt, vjs 1 , xÞ, (2) mrisk * 0 ðt, vjs 1 , xÞ, and (3) ϕðt, vjs 1 , xÞ in the transport formula modularly measure distinct scientific elements, we stated the sufficient conditions 3(B) and 3(C) in terms of capturing the effect modifiers of vaccine efficacy in the original Phase III trial [factor (1)] and capturing the prognostic factors in the new setting [factor (2)], combined with correctly specifying the bridging assumption function ϕðÁÞ for these selected variables [factor (3)]. Because the effect modifiers and prognostic factors may be different for different disease types v, the practioner must seek to include all modifying covariates for any type V = v of disease. In particular, this is seen by expressing 3(B) as follows. Let X all and S all ð1Þ represent all participant covariates at baseline and time τ under vaccine assignment, measured or unmeasured, and similarly let V all represent all pathogen features at the time of the disease endpoint. Then 3(B) states that (X, Sð1Þ, V) and (X * , Sð1 * Þ, V * ) used in the transport formula satisfy
VEðt, V all ð0Þ = vjS all ð1Þ = s all 1 , X all = x all , Sð1Þ = s 1 , X = xÞ = VEðt, Vð0Þ = vjSð1Þ = s 1 , X = xÞ and mrisk
For specifying ϕðt, vjs 1 , xÞ in critical assumption 3(C), note that, in principle, ϕðt, vjs 1 , xÞ should approximately equal 1 in the hypothetical scenario that ðX all , S all ð1Þ, V all Þ were used in the transport formula, because after all characteristics are accounted for there are no remaining factors to create differential vaccine efficacy in the two settings. Thus, the scientist aims to select sufficiently rich ðX, Sð1Þ, VÞ to make ϕðt, vjs 1 , xÞ plausibly near one and to narrow the range of the sensitivity analysis that varies ϕðt, vjs 1 , xÞ. 3(C) with ϕðt, vjs 1 , xÞ = 1 is more readily credible for applications where the identical vaccine is tested in the original and new settings. Estimation via the transport formula combines empirical evidence with a bridging assumption, where consistent estimation may be obtained if ϕðÁÞ is correctly specified, e. g., as unity. For bridging to a new vaccine in the same setting, such a "perfect bridging assumption" ϕðÁÞ = 1 states that, within each baseline subgroup X = x, a vaccine-induced immune response of Sð1Þ = s 1 corresponds to the same level of protective efficacy whether the original vaccine or new vaccine generated the response. This interpretation naturally extends for bridging to a new vaccine in a new setting. Carroll et al. (2006) defined transportability in the measurement error problem context where measurement error from one study can be corrected using information on the measurement error process from independent data. They stated that parameters of a model can be transported from one study to another if the model holds with the same parameter values in both studies. Carroll et al.'s (2006) transportability assumption corresponds to our perfect bridging assumption ϕðÁÞ = 1, where the vaccine efficacy model as a function of X and Sð1Þ is the same between the original setting and the new setting.
In the special case of no right-censoring, no mark V, and no clinical events before τ, the above transport formula collapses to the formula of Huang et al. (2013) based on S alone, which is similar to a formula in Follmann (2006) . In addition, with no V, no clinical events before τ, and a different type of perfect bridging assumption, our transport formula is similar to one of Pearl and Bareinboim's (2011) transport formulas (their eq. for z = 0, 1, which makes a perfect bridging assumption of invariant ðs, xÞ − specific average causal effects in the two settings [surmised to be PðYð1 * Þ = 1jSð1 * Þ = s, X * = xÞ − PðYð0 * Þ = 1jSð0 * Þ = s, X * = xÞ = PðYð1Þ = 1jSð1Þ = s, X = xÞ − PðYð0Þ = 1jSð0Þ = s, X = xÞ]. This formula is the same as ours for mrisk . In addition, the uncertainty in the bridging estimation can be quantified by accounting for multiple uncertainty sources including estimator sampling variability, potential misspecification of models used in estimating VEðt, vjs 1 , xÞ and mrisk * 0 ðt, vjx 1 , xÞ, partial non-identifiability of VEðt, vjs 1 , xÞ, and potential misspecification of ϕðÁÞ. Below we implement this via bootstrap-based procedures for obtaining estimated uncertainty intervals (EUIs) (Vansteelandt et al. 2006 ).
Plausibility and evaluation of the no-early-VE and common support assumptions
The No-early-VE assumption is often violated in trials with a series of vaccinations and τ substantially after baseline, given the accrual of protective immunity over time. It is straightforward to diagnose a violation, by testing if vaccine efficacy by τ differs from 0. If relatively few clinical events happen by τ this violation may only minorly bias results; otherwise use of the method removing the No-early-VE assumption may be warranted.
The multivariate nature of (X, Sð1Þ, V) makes it challenging to check the common support assumption. For each marginal univariate distribution of the components of X and Sð1Þ, methods in the literature for testing for a common support of two distributions could be used, for example accessing tests of "support overlap" in the propensity score matching causal literature. These diagnostic procedures can be carried out because samples of (X, Sð1Þ) and (X * , Sð1 * Þ) are available. In addition, domain knowledge aids in checking the assumption; for example immunological assays used to measure Sð1Þ typically have lower and upper quantification readout limits, and based on knowledge of the vaccine regimens and immunology it may be expected that the whole range would be represented in both settings. The more challenging problem involves checking the support assumption in terms of the mark variable V. Whereas a sample of (X, Sð1Þ, V) is available, as is a sample of (X * , V * ), no sample is available for (X * , Sð1 * Þ, V * ) in the new setting, because the Phase I trial that measures Sð1 * Þ is not designed to capture clinical endpoints and hence measure V * . Consequently, domain knowledge is necessary for judging credibility of the common support assumption, which cannot be fully empirically checked until the future Phase III trial is conducted. If V is discrete categorical and is highly represented among circulating pathogen types in both the original and new settings across the levels of X, then the assumption may be quite plausible.
4 Estimation of the terms in the transport formula 4.1 Estimation of the mark-specific VE curve in the original phase III trial Qin et al. (2008) and Gabriel et al. (2014 Gabriel et al. ( , 2015 developed methods for estimation of VEðtjs 1 , xÞ from an efficacy trial, accommodating the right-censoring of T. These papers did not consider competing risks data but could be straightforwardly extended to estimate VEðt, vjs 1 , xÞ for a discrete V via a cause-specific Cox proportional hazards model (Prentice et al. 1989) . For the application we apply an alternative, new method for estimating VEðt, vjs 1 , xÞ for the special case of a dichotomous mark V (with levels 0 and 1) based on structural multinomial logistic regression modeling (described in Supplementary Materials D) . 
Estimation of background disease risk in the new setting
Estimation of mrisk * 0 ðt, vjs 1 , xÞ is a challenging problem, because it is not possible for epidemiological data to be available for direct empirical estimation, due to the basic fact that the follow-up Phase III trial will occur in the future. However, epidemiological data on recent background disease incidence for V * = v-specific disease within baseline covariate levels X * = x in the new setting can be used for estimation of The idea of Approach 1 is to shift the problem from estimation of mrisk ðt, vjxÞ must be based on epidemiological data in the new setting that depends on the quality of surveillance for incident disease cases and on the cataloging of the types v of disease cases. The numerator of w Inc ðtjxÞ may be estimated based on an epidemiological cohort study in the new setting, and the denominator through straightfoward analysis of the original Phase III trial. Because risk 0 ðtjxÞ appears in the denominator of w Inc ðtjxÞ, estimation could be unstable if risk 0 ðtjxÞ is close to zero; thus reasonably precise estimation of risk 0 ðtjxÞ for each x is needed (which is achieved in the RV144 Example due to ample sample size). The numerator of w V ðt, vjxÞ may be estimated from a genomic epidemiological study of circulating pathogen types in the new setting, and denominator either through a genomic epidemiological study in the original setting or through straightforward analysis of the original Phase III trial.
Our Approach 2 to estimating mrisk 
Sensitivity analysis to the perfect bridging assumption
Given that direct data on clinical efficacy for the new setting of interest are not available, theories of mechanisms of protection, as encoded in the specified bridging assumption function ϕðÁÞ, must be combined with empirical data to make bridging inferences. Because the form of ϕðÁÞ cannot be directly estimated until the new efficacy trial, a sensitivity analysis is warranted. One approach specifies a fixed constant Γ and estimates VE * ðtÞ under each of a grid of constants γ 2 ½ (3) immune responses induced by the vaccine regimens; (4) host immune genetics; (5) participant demographics including country, race/ethnicity, gender, BMI, and level and pattern of HIV risk-taking behavior (RV144 participants were Thai, low risk, and low BMI whereas HVTN 702 participants will be mostly Black South African, high risk, and higher BMI for women); and (6) intensity of HIV exposure (much higher exposure in HVTN 702). We select V as the indicator of whether the amino acid (AA) at position 169 in an HIV infected individual's V2 Envelope HIV sequence sampled at diagnosis of infection mismatches the corresponding AA in the HIV strains contained in the vaccine (Rolland and Edlefsen et al. 2012 ). In addition, we select S as the magnitude of binding antibodies to the V1V2 portion of a gp70-scaffolded Envelope protein (Haynes et al. 2012) , and select X as the indicator of whether an individual carried a CC or TT (CT/TT) genotype at position 126 in intron 2 of the Fc-γ receptor 2C gene locus (Li et al. 2014 ). These choices are based on published results that the vaccine efficacy in RV144 significantly depended on these variables after multiplicity correction (see Supplementary Materials A for details).
For the input terms VEðt = 39, vjs 1 , xÞ, for v = 1, we set c VEðt = 39, v = 1js 1 , xÞ = 0 for all s 1 and x, because c VEðt = 39, v = 1Þ = − 0.55 (95% CI = -2.58 to 0.33); this choice invokes the assumption that the vaccine did not increase the risk of v = 1 HIV infection (which "de-noises" the estimation). Alternatively, VEðt = 39, v = 1js 1 , xÞ could be estimated similarly as VEðt = 39, v = 0js 1 , xÞ without making the assumption of zero vaccine efficacy against type v = 1 HIV. For v = 0, we set c VEðt = 39, v = 0js 1 , xÞ based on estimation methods described in Section 4.2 and Supplementary Materials B and D; Figure 1 shows c VEðt = 39, v = 0js 1 , xÞ as a function of Sð1Þ = s 1 for the subgroups x = 0 (CC genotype) and x = 1 (CT/CT). The estimation approach assumes VEðt = 39, v = 0js 1 = 0, x = 0Þ = 0, which is the "average causal necessity" scenario (Gilbert and Hudgens 2008) for the x = 0 subgroup. We could alternatively carry out the estimation enforcing an additional assumption of ACN for X = 1 as well as for X = 0, but it is not necessary for identifiability, such that we leave the risk for the S(1) = 0, X = 1 subgroup to be estimated. (Here we seek to only specify the minimum assumptions needed to achieve identifiability.) In the RV144 trial, vaccine efficacy for the X = 0 subgroup was estimated to be near 0 whereas vaccine efficacy for the X = 1 subgroup was estimated to be well above 0, making it more consistent with empirical data to assume ACN for X = 0 but not for X = 1. Below we also report a sensitivity analysis that instead assumes average causal necessity for the x = 1 subgroup.
We estimate F * ðs 1 jxÞ and H * ðxÞ based on the ongoing HVTN 100 Phase IIa trial. HVTN 100 is enrolling 212 vaccine recipients, and will measure baseline covariates X * in all of these participants and immune responses Sð1 * Þ in all who attend the Month 6 visit HIV negative (i. e., with minðT * , C * Þ > 6 months). Because the data are not yet available for HVTN 100, for illustrative purposes we first use the data from the RV144 trial [assuming Sð1 estimates of F * ðs 1 jxÞ for each subgroup x = 0, 1 in RV144. We estimate H * ðxÞ based on a Fc-γ receptor genetics in a sample of n = 131 Black South Africans (Lassauniere et al. 2014) . Because 49 % carried CT or TT, we set b PðX * = 1jTð1 * Þ > τ, Tð0 * Þ > τÞ = 0.49 (compared to 0.28 in RV144; Table S8 of Li et al. 2014 ).
Supplementary Materials A describes the full details of the methods used for estimation of mrisk * 0 ðt = 39, vjs 1 , xÞ for each v, x 2 f0, 1g via eq.
[5], which we accomplish by assuming the equipercentile model for F * ðs 1 jxÞ described in Section 4.3 and estimating the three terms w Inc ðtjxÞ, w V ðt, vjxÞ, and mrisk 0 ðt, vjs 1 , xÞ separately. The numerator of w Inc ðtjxÞ is estimated from a recent HIV vaccine efficacy trial in South Africa (Gray et al. 2014) in a study population expected to be similar to the HVTN 702 study population, and the denominator is estimated from RV144. Table 2 . We apply the transport formula under the perfect bridging assumption ϕðÁÞ ≡ 1 by plugging the estimated terms into the formula [3], yielding c VE * ðt = 39Þ = 0.35 with 95 % bootstrap confidence interval 0.11-0.66.
(See Supplementary Materials E for a description of the bootstrap procedure.) As a sensitivity analysis, we repeated the analysis for a grid of fixed γ = ϕðt, vjs 1 , xÞ values varying between 1 Γ and Γ with Γ = 1.25 ( Figure  3(a) ), which gives an estimated ignorance interval of 0.28-0.43 and a 95 % EUI of 0.09-0.82. Next, we repeated the analysis of Figure 3 Because HVTN 100 has not yet completed, the data from RV144 were used.
4
The estimates are the same for x = 0 and x = 1 because data on X were not available in the HVTN 503 trial. increasing for the scenarios with increased V2 immune responses in the new setting. Thus, the overall result is that vaccine efficacy is predicted to be slightly higher in the new setting than was previously observed in RV144 (also summarized in Table 3 ). This only-slight increase is explained by the fact that the VE curves only slightly increased with Sð1Þ (Figure 1 ), limiting the impact of improving V2 responses, combined with the facts that c VEðt, v = 1js 1 , xÞ = 0 for all ðs 1 , xÞ and the frequency of v = 1 is greater in South Africans (40 %) than Thais (28 %).
To examine the common support assumption 3(A), note that the BAMA assay used for measuring Sð1Þ has lower and upper readout limits, and from RV144 we directly observed that Sð1Þ takes values over the whole range for each subgroup X = 1 and X = 0. Moreover, we know that Sð1 * Þ also takes values over the whole range for each subgroup X * = 1 and X * = 0, by the way we simulated the data. Lastly, V is simple, being binary, and the data on (X, V) and (X * , V * ) show that each of the four possible levels is wellrepresented in each of the original and new settings. Taken together these results strongly suggest (but do not prove) the common support assumption. We repeated the analysis assuming average causal necessity (ACN) for the x = 1 (higher protected) subgroup instead of for the x = 0 subgroup ( Figure 4, Table 3 ). Now the increase in V2 immune responses The estimation is done as described in Sð1Þ leads to a greater increase in estimated VE * ðt = 39Þ, which occurs because the estimated VEðt = 39, v = 0js 1 , x = 1Þ curve is steeper than in the previous analysis. We also consider the scenario where all vaccine recipients achieve Sð1 * Þ in the highest region of possible immune responses supported by the binding assay, uniformly distributed between 9 and 10.1 (10.1 is the upper quantification limit of the assay). This scenario represents a case where a "putatively much stronger" vaccine is identified in HVTN 100. The predicted VE * ðt = 39Þ increases by 20 % to 30 % (Table 3) .
Lastly, to illustrate how the method can be used to project what overall vaccine efficacy could be achievable if additional HIV strains are added to a refined multivalent version of the vaccine regimen, we consider the scenario that a v = 1 HIV strain is added to the vaccine construct. This follows the paradigm for traditional vaccinology to put multiple pathogen genotypes in a vaccine to broaden protection against genetically diverse pathogens (e. g., Capeding et al. 2014; Villar et al. 2015) . We consider the scenario that the v = 1 and v = 0 strains protect equally well against pathogen-matched type v disease, expressed as VEðt, v = 1js 1 , xÞ = VEðt, v = 0js 1 , xÞ. As such, in implementing the transport formula we use an estimated VEðt, v = 1js 1 , xÞ equal to the estimated VEðt, v = 0js 1 , xÞ in the previous analyses. The resulting estimated ignorance intervals for the scenarios in Figures 3(d) and 4(d) are now 0.42-0.65 and 0.44-0.70, respectively (Table 3 ). The predicted VE * ðt = 39Þ majorly increases because 40 % of the circulating HIV-1s in South Africa are of type v = 1, against which a vaccine without a v = 1 strain confers no protection.
Discussion
This article develops an immuno-bridging transport formula for predicting overall vaccine efficacy VE * ðtÞ in a new setting based on a previous Phase III vaccine efficacy trial(s) and a Phase I/II biomarker endpoint trial in the new setting, plus epidemiological data on disease incidence in the new setting and genomic epidemiological data on the pathogen genotypes in the previous and new settings. One application is quantifying uncertainty about predicting VE * ðtÞ in the absence of an efficacy trial, explaining in specific and component terms the challenges posed to reliably inferring VE * ðtÞ in a new setting without directly estimating VE * ðtÞ from clinical endpoint data. A second application is "Go/No-Go" decision-making about whether a new vaccine tested in a Phase IIa trial should be advanced to an efficacy trial in the original or new setting (elaborated in Supplementary Materials F). For example, the HVTN is testing multiple candidate HIV vaccines in Phase I/II trials in South Africa with objective to down-select up to three vaccines into an efficacy trial. The transport formula provides a criterion for advancement, where regimens with higher estimated VE * ðtÞ would be favored. While this article focuses on the vaccine field, the Go/No-Go application is of broad relevance across clinical trials research. A third highly related application is guidance for selecting study endpoints in Phase I/II vaccine/treatment trials prior to the next efficacy trial; for example biomarkers Sð1Þ that are stronger effect modifiers of vaccine/treatment efficacy in the previous efficacy trial (s) may be preferred.
6.1 Which variables (X , Sð1Þ, V ) to include in the transport formula?
A basic challenge posed to applying the transport formula is how to choose the baseline covariates X, intermediate response endpoints Sð1Þ, and marks V to make the formula accurate? As stated above, for validity the ðX, Sð1ÞÞ selected for use in the transport formula must be the only effect modifiers of markspecific vaccine efficacy in the original and new settings and be the only prognostic factors for disease in the new setting, for each type V of disease. This condition implies that application of the formula depends on the integration of subject-matter knowledge. Selecting ðX, Sð1Þ, VÞ will generally be easier when the new setting entails a nearly identical vaccine as studied originally, and more difficult for a new vaccine, moreso the extent to which it differs from the original vaccine. Pearl and Bareinboim (2011) provide various criteria for covariates that are necessary to include versus necessary to not include.
In practice, often particular Sð1Þ variables are known to be strong effect modifiers of VEðt, vÞ, making it obvious to pick these variables. Moreover, commonly vaccine efficacy is known to vary with a particular pathogen feature V such as serotype, making it obvious to include this feature. A recent dengue vaccine efficacy trial illustrates this situation, which tested a vaccine containing four dengue strains, one of each serotype (Capeding et al. 2014; Villar et al. 2015) . The trial assessed vaccine efficacy against each serotype v = 1, 2, 3, 4, and measured the level of neutralization to each of the four dengue strains in the vaccine (four variables S v ð1Þ, v = 1, 2, 3, 4). Prior to the trial, the dengue vaccine field had knowledge that for each v = 1, 2, 3, 4, VEðt, vjs 1 , xÞ would likely be higher for subgroups with higher levels of S v ð1Þ = s 1 .
How to handle the dimensionality of X?
If X is discrete categorical with a reasonable amount of data support at each level, then the transport formula can be applied without invoking parametric models for the conditional distribution of Sð1Þ given X, and mrisk z ðt, vjs 1 , xÞ can be estimated separately for each x. However, if X is higher dimensional, then some parametric modeling assumptions are needed, and if X is high dimensional, then specialized p > n regression models are needed. One approach to addressing both issues would estimate mrisk z ðt, vjs 1 , xÞ using a supervised statistical learning approach that considers a large set of potential models defined by different sets of the covariates within X and different models, for example using nonparametric loss-based ensemble learning (van der Laan et al. 2007) , with cross-validated area-under-the ROC curve as a criterion for model selection (van der Laan et al. 2013) . Existing supervised statistical learning methods may be applied to estimate mrisk 1 ðt, vjs 1 , xÞ given the identifiability of this parameter from the observed data. For mrisk 0 ðt, vjs 1 , xÞ, additional research would be needed given the identifiability challenge.
How to specify the bridging assumption function ϕðÁjÁÞ?
For the transport formula to work well in applications it is neccesary that the bridging assumption function ϕðt, vjs 1 , xÞ = VE * ðt, vjs 1 , xÞ=VEðt, vjs 1 , xÞ can be meaningfully specified and varied in a sensitivity analysis.
We suggest that if ϕðt, vjs 1 , xÞ is approximately a ratio of multiplicative vaccine-reductions in average markspecific per-exposure probabilities of acquisition of the pathogen under study, then ϕðÁjÁÞ can be interpreted as a "pure biological susceptibility" parameter akin to a challenge trial, thus making a default assumption ϕðt, vjs 1 , xÞ = 1 reasonable given carefully selected ðX, Sð1Þ, VÞ, and facilitating an interpretable sensitivity analysis. This biological parameter approximation is more accurate for a rare event trial (Gilbert 2001) , suggesting that the formula may be most appropriate for such settings, which are the norm in vaccine efficacy trials. Moreover, while our approach focuses on cumulative vaccine efficacy parameters, the approach could be adapted to instead use proportional mark-specific hazards vaccine efficacy parameters (Gilbert and Sun 2014) , and applied to settings where the proportional hazards assumption is approximately true (e. g., Capeding et al. 2014; Villar et al. 2015) . The advantage of the hazard ratio approach is that ϕðt, vjs 1 , xÞ has a closer approximation to a ratio of average per-exposure vaccine efficacies (Gilbert 2001 ). However, a disadvantage is that the proportional hazards VE parameter is only a causal effect of treatment assignment under a strong assumption that will fail if there is treatment efficacy, such that it is only an approximately causal approach (Hernán 2010) ; whereas in contrast the cumulative vaccine efficacy approach is based on true causal effects.
VE curve principal stratification versus observables-only transport formula
Our transport formula is based on VE curves VEðt, vjs 1 , xÞ that measure vaccine efficacy in sub-populations defined by ðX, Sð1ÞÞ, which are not identifiable from the standard assumptions in the Phase III efficacy trial and the observed data, because the vaccine-induced immune responses Sð1Þ are not directly measurable in placebo recipients (Follmann 2006) . The rationale for this approach is that for many vaccine fields one or more immune response biomarkers are known or hypothesized to be (very) strong effect modifiers of vaccine efficacy (Plotkin 2010) , and the principal stratification framework studies treatment effect modification across such post-randomization subgroups (Frangakis and Rubin 2002; Gilbert and Hudgens 2008; Gilbert et al. 2015) . To avoid the identifiability challenge, an alternative transport formula would be based purely on parameters identifiable from the standard assumptions and observed data. However, a challenge posed to this observables approach is how to specify an interpretable bridging function that expresses a perfect bridging scenario as a special case and provides a basis for sensitivity analysis? A difficulty is that bridging functions based purely on observables may aggregate biological and behavioral/ecological differences between the old and new settings, which may be dominated by behavioral/ecological factors; for example in the HIV vaccine illustration the cumulative infection rate in placebo recipients is approximately 10 times higher in the new setting than the old setting. Nevertheless, the "purely observables" approach certainly merits full investigation, given its advantage in avoiding the use of partially non-identified parameters, and it is beyond the scope of this work to make this comparison. We do note, however, that under our Approach 2 for estimating mrisk * 0 ðt, vjs 1 , xÞ described in Section 4.3, our transport formula is a version of an observables-only transport formula, because with this approach VEðt, vjs 1 , xÞ is identified from the standard assumptions in randomized trials. In addition, if the principal stratification framework is deemed unappealing for an application but controlled effects can be well-defined and are appealing, our alternative version of the transport formula based on controlled effects may be considered (Supplementary Materials A).
Transport formula under the no-early-harm assumption
Supplementary Materials G develops the transport formula relaxing the No-early-VE assumption to the Noearly-harm monotonicity assumption, showing that the formula becomes more complicated, for example involving three bridging assumption functions instead of one. Therefore the problem of immuno-bridging is majorly simplified if one can at least approximately assume no vaccine efficacy by the time τ that immune responses/intermediate endpoints are measured. Accordingly, most of the principal surrogate endpoint evaluation literature has assumed No-early-VE or has considered the simplified scenario that no clinical events happen before the potential surrogates are measured. The current research indicates that in some settings this issue must be accounted for to achieve a cogent transport formula, for example in the two Phase III dengue vaccine efficacy trials mentioned above, the immune responses were measured far after randomization (τ = 13 months) and No-early-VE was clearly majorly violated (Capeding et al. 2014; Villar et al. 2015) . The simpler transport formula will be most easily justified in settings where strong effect modifying biomarkers are available shortly after vaccine/treatment initiation, for which No-early-VE may be justified, or minor violations will not materially affect the bridging prediction. Moreover, the controlled effects approach may be best suited to settings where no or very few clinical events occur before τ, given the difficulty in conceiving of the intervened biomarker-specific vaccine efficacy curve otherwise.
Final remarks
Implementation of the proposed transport formula entails estimation of ignorance intervals and uncertainty intervals, in order to account for sampling variability as well as for: (1) partial non-identifiability of the mark-specific conditional vaccine efficacy curve VEðt, vjs 1 , xÞ, (2) uncertainty in the assumptions used to estimate mrisk * 0 ðt, vjs 1 , xÞ, and (3) possible deviations from the perfect bridging assumption. This research shows that, even under No-early-VE, a large amount of data from the original efficacy trial(s) is needed for precise estimation of VE * ðtÞ, highlighting the importance of conducting direct clinical endpoint Phase III trials. However, the identical immuno-bridging formula applies if a set of previous efficacy trials is used instead of a single efficacy trial, where trial-level and subject-level features of the trials can be included as covariates in the transport formula. In some areas of clinical research, meta-analysis data are available from a large number of mega-trials (Staessen et al. 2005) , illustrating that, in principle, it is possible in practice to generate the requisite data for obtaining relatively precise inferences.
